A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06589778 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: SHR-A2102
DRUG: Adebelimab (SHR-1316)
DRUG: SHR-8068

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.